Effect of Agalsidase Alfa Replacement Therapy on Fabry Disease-Related Hypertrophic Cardiomyopathy: A 12-to 36-Month, Retrospective, Blinded Echocardiographic Pooled Analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F09%3A4230" target="_blank" >RIV/00216208:11110/09:4230 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/09:4230
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Effect of Agalsidase Alfa Replacement Therapy on Fabry Disease-Related Hypertrophic Cardiomyopathy: A 12-to 36-Month, Retrospective, Blinded Echocardiographic Pooled Analysis
Original language description
The study summarizes blinded echocardiuographic analysis of long-term follow-up in patients with Fabry disease treated with alalsidase alfa. In a subset of patients, the study confirmed beneficial results on left ventricular hypertrophy.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2009
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Therapeutics
ISSN
0149-2918
e-ISSN
—
Volume of the periodical
31
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
—
UT code for WoS article
000271043100007
EID of the result in the Scopus database
—